Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

TR BioSurgical, LLC Develops Breakthrough Osteoarthritis Implant
TR BioSurgical, LLC, announced highly encouraging results using their new medical device (bioscaffold) in canine patients with advanced osteoarthritis. The new bioscaffold is implanted in or near diseased tissue and provides a structural matrix for local repair cells, such as stem cells or fibroblasts, to attach and heal tissue by local, physiological repair mechanisms. The new bioscaffold implant contains no drugs, cells or growth factors and is eventually resorbed by the infiltrating cells. The implant is made from a proprietary, copolymerized collagen and is sterile, cost effective, and non- immunogenic.

World Heart Federation Warns That Burden Of Tobacco Epidemic Continues To Worsen Societies And Economies
G-20 leaders pledged to provide the International Monetary Fund with $500
News of the day
BMA Poll Reveals The Public's Fear For Future Of The NHS, UK
A nationwide public opinion poll conducted by Hamilton Lock for the British Medical Association released has revealed how worried the public is about future funding of the health service in light of the recession.
Mental Health

CorNova(R) Receives CE Mark Approval For Valecor Platinum(R) Coronary Stent System

CorNova Inc. announced that it has received CE mark approval for its Valecor Platinum Coronary Stent System. The Valecor Platinum is a next-generation cobalt-chromium bare-metal stent. Utilizing a novel ion-based implantation technology called Nanofusion(TM), the Valecor Platinum stent presents a pure platinum surface to both the lumen and artery wall to provide protection from less biocompatible components inherent in all medical-grade alloys. Platinum is known for its superior biocompatibility and biostability. In addition, the stent offers some of the thinnest struts available and a novel open cell design that maximizes flexibility and conformability, while causing minimal inflammation and tissue damage during deployment. "The Valecor Platinum Coronary Stent System represents a major advancement over current offerings in the relatively undifferentiated $1 billion bare stent market," said S. Eric Ryan, M.D., chairman and chief executive officer of CorNova. "Because of its highly biocompatible platinum surface and its novel open cell design, it has shown superior anti-restentotic performance compared to leading bare metal stents in preclinical studies." About CorNova CorNova is a developer of next-generation endovascular products designed to integrate new technologies into existing products and procedures, resulting in better patient outcomes without added procedure time, cost and patient risk. The company"s FiberHalo(TM) stent deployment and post-dilatation angioplasty balloon catheters are designed to provide stent lumen area measurement within the angioplasty catheter itself. CorNova is also developing a pre-dilatation version of the FiberHalo catheter that can detect the potential of mechanical failure that would allow for treatment prior to stent placement and the Valecor Platinum(TM) Coronary Stent, an advanced "bare-metal stent" with an ion-infused pure platinum surface that has shown superior performance and anti-restenoic properties compared to current bare-metal stents. CorNova Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009